Effects of topical administration of levocabastine on psychomotor and cognitive function.
The possible central nervous system effects of topical administration of levocabastine, a new H1-antagonist, were investigated in a double-blind, placebo-controlled, crossover study using a battery of objective and subjective tests. These were carried out in 12 volunteers up to five hours postapplication. Neither the recommended (0.5 mg/mL) nor the four times higher (2.0 mg/mL) concentration level was found to be distinguishable from placebo, while the verum (triprolidine 10 mg) was significantly worse, on both objective and subjective measures.
Rombaut
N
N
Human Psychopharmacology Research Unit, Robens Institute, University of Surrey, England.
Bhatti
J Z
JZ
Curran
S
S
Hindmarch
I
I
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D003071:Cognition / Q000187:drug effects / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology*; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology*
D006634:Histamine H1 Antagonists; D010880:Piperidines; C047340:levocabastine